Skip to main content
TipRanks
Go Ultimate75% OFF

Top Page

XPH

SPDR S&P Pharmaceuticals ETF (XPH)

Rating:58Neutral
Price Target:$67.00â–²(0.25% Upside)

XPH’s rating reflects a mix of solid, established pharma names and more financially challenged companies. Strong contributors like Eli Lilly and Zoetis, which show robust financial performance and strategic initiatives such as dividends and share repurchases, help support the fund’s quality. However, weaker holdings like Xeris Pharmaceuticals, with high leverage and negative equity, and others facing profitability or cash flow issues add risk, and the fund’s focus on the pharmaceutical sector means investors are exposed to sector-specific pressures.

Positive Factors
Strong Year-to-Date PerformanceThe ETF has delivered strong gains so far this year, showing solid momentum in the pharmaceuticals space.
Healthy Mix of Established and Smaller Pharma CompaniesTop holdings include both well-known drug makers and smaller, more specialized firms, offering a blend of stability and growth potential.
Focused Healthcare ExposureThe fund is heavily invested in the health care sector, giving targeted exposure to pharmaceuticals for investors who want to bet on this industry.
Negative Factors
Recent Short-Term WeaknessPerformance over the last month and quarter has been weak, which may signal near-term volatility or pressure on the sector.
Single-Country ConcentrationAlmost all assets are invested in U.S. companies, which increases reliance on the U.S. market and limits global diversification.
Sector Concentration RiskWith most of its holdings in health care and pharmaceuticals, the ETF is highly sensitive to industry-specific risks such as regulation and drug pricing changes.

XPH vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%50%SPY+14.55%XPH+28.79%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AUM
528.86M
Region
North America
Expense Ratio
0.35%
Beta
0.77
Issuer
SPDR
Inception Date
Jun 19, 2006
Dividend Yield
0.41%
Asset Class
Equity
Index Tracked
S&P Pharmaceuticals Select Industry

XPH Summary

XPH is the SPDR S&P Pharmaceuticals ETF, which follows the S&P Pharmaceuticals Select Industry index. It focuses on U.S. drugmakers, from smaller innovators to big, well-known names like Eli Lilly and Pfizer. By investing in XPH, you get a basket of pharmaceutical companies in one trade, which can offer growth potential tied to new medicines and rising health care needs, along with diversification within the drug sector. However, because it is heavily focused on pharmaceuticals, its price can go up and down sharply with changes in drug approvals, regulation, and overall health care market sentiment.

How much will it cost me?

This ETF has an expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 you invest. That’s higher than the cost of a typical broad, passively managed index ETF because this fund focuses on a specialized pharmaceuticals sector index, which usually comes with slightly higher fees.

What would affect this ETF?

XPH could benefit from growing health care demand, an aging population, and successful new drugs from its U.S. pharmaceutical holdings like Eli Lilly, Pfizer, and smaller specialty firms, especially if regulations remain supportive of innovation and insurance coverage. On the downside, tighter drug pricing rules, patent expirations, safety or approval setbacks, and broader market or economic stress in the U.S. could hurt profits and weigh on the ETF’s performance.

XPH Top 10 Holdings

XPH is a pure play on U.S. pharmaceuticals, and its story right now is driven more by nimble drug developers than by household names. Pacira and Amneal have been rising steadily, giving the fund a solid lift, while Ligand and Viatris add to the momentum with improving trends despite some valuation worries. On the flip side, Maze Therapeutics has been lagging, acting like a small anchor on an otherwise upbeat portfolio. With Eli Lilly as a steady blue-chip presence, the ETF is clearly concentrated in pharma innovators rather than broad health care giants.

XPH top ten holdings
NameCompany NameWeight %Market ValueMarket CapYearly GainOverall Rating
XERSXERSXeris Pharmaceuticals4.30%$22.76M$3.04B129.48%46Neutral
MANEMANEVeradermics, Incorporated2.70%$14.31M$5.47B243.47%――
MAZEMAZEMaze Therapeutics, Inc.2.60%$13.77M$1.88B7.82%59Neutral
LLYLLYEli Lilly & Co2.53%$13.38M$1.36T41.12%72Outperform
VTRSVTRSViatris2.49%$13.20M$23.87B90.83%60Neutral
PCRXPCRXPacira Pharmaceuticals2.53%$13.39M$1.46B54.36%69Neutral
AMRXAMRXAmneal Pharmaceuticals2.50%$13.26M$7.45B85.59%58Neutral
SEPNSEPNSepterna, Inc.2.05%$10.87M$2.03B121.41%61Neutral
ETONETONEton Pharmaceuticals2.08%$11.01M$1.84B278.73%56Neutral
RPRXRPRXRoyalty Pharma2.27%$12.00M$39.76B74.45%79Outperform

XPH Technical Analysis

Technical Analysis SentimentPositive
Last Price66.83

Price Trends

50DMA65.41Positive
100DMA67.38Negative
200DMA62.15Positive

Market Momentum

MACD0.65Negative
RSI55.28Neutral
STOCH78.93Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XPH, the sentiment is Positive. The current price of 66.83 is above the 20-day moving average (MA) of 64.87, above the 50-day MA of 65.41, and above the 200-day MA of 62.15, indicating a bullish trend. The MACD of 0.65 indicates Negative momentum. The RSI at 55.28 is Neutral, neither overbought nor oversold. The STOCH value of 78.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XPH.

XPH Peer Comparison

Comparison Results

XPH against its peer funds
NamePricePrice TargetAUMExpense RatioOverall Rating
XPHXPH$66.83$67.00(0.25% Upside)$528.86M0.35%58Neutral
PJPPJP$131.04$161.99(23.62% Upside)$609.17M0.58%70Neutral
PBEPBE$97.88$127.65(30.41% Upside)$436.74M0.59%71Outperform
PINKPINK$39.98$52.19(30.54% Upside)$344.66M0.51%67Neutral
PTHPTH$57.32$78.31(36.62% Upside)$284.20M0.60%60Neutral
XHSXHS$145.43$171.17(17.70% Upside)$244.82M0.35%65Neutral

Performance Comparison

0%20%40%XPHPJPPBEPINKPTHXHSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
XPH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
XPHSPDR S&P Pharmaceuticals ETF66.8315.6830.67%
PJPInvesco Dynamic Pharmaceuticals ETF131.0429.0728.51%
PBEInvesco Dynamic Biotechnology & Genome ETF97.8821.5428.21%
PINKSimplify Health Care ETF39.983.9611.00%
PTHInvesco DWA Healthcare Momentum ETF57.318.6117.68%
XHSSPDR S&P Health Care Services ETF145.4344.0243.41%
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.